DURGA-6
Research type
Research Study
Full title
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)
IRAS ID
1013977
Contact name
Assim Khan
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
This is a research study sponsored and funded by AstraZeneca AB and will run globally at hospital centres, including sites in the UK, with expertise in multiple myeloma, cellular therapies, and stem cell transplantation. The study may run for up to 13 years globally.
The study is looking for better treatment options for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (using their own stem cells) and whose disease has not worsened after initial treatment.
Multiple myeloma is a cancer of plasma cells in the blood. Standard treatment usually includes initial drug therapy, followed by high‑dose chemotherapy, a stem cell transplant and ongoing maintenance treatment with lenalidomide. This study is testing AZD0120, a type of treatment called chimeric antigen receptor T-cell (CAR-T). AZD0120 is made using a patient’s own immune cells, which are collected from the blood and modified to recognise and kill cancer cells. These cells are then returned to the patient through a needle into a vein.
The aim of the study is to assess whether a single treatment with AZD0120 after initial therapy, followed by maintenance treatment, can control multiple myeloma for longer and be easier to tolerate than the current standard treatment. This will be assessed by looking at how long patients live without their myeloma worsening and how many patients have no signs of cancer nine months after receiving either AZD0120 or transplant.
A computer program will randomly (similar to drawing a name from a hat) assign the treatment each participant receives – stem cell transplant or AZD0120. Participants and trial doctors will know what each participant is receiving. Those who receive AZD0120 may be asked to take part in long‑term follow‑up for up to 15 years after receiving AZD0120.
Participants must be at least 18 years old and have NDMM. Some medical conditions may prevent participation if the study would be unsafe.
REC name
North East - York Research Ethics Committee
REC reference
26/NE/0062
Date of REC Opinion
9 Jun 2026
REC opinion
Further Information Favourable Opinion